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Abstract
Objectives:  To  evaluate  the  association  between  oxidative  and  inﬂammatory  stress  markers
with peri-intraventricular  hemorrhage  (PIVH)  in  very-low  birth  weight  newborns.
Methods:  This  was  a  prospective  study  conducted  in  a  level  III  neonatal  unit.  Basal  and  stimu-
lated reactive  oxygen  intermediates  (ROIs),  reduced  glutathione  (GSH),  and  interleukin-6  (IL-6)
levels were  measured  in  umbilical  cord  blood.  Newborns  underwent  serial  ultrasound  at  the
bedside,  at  6,  12,  24,  and  72  hours  of  life  and  at  seven  days  for  the  diagnosis  of  PIVH,  classiﬁed
as grades  I  to  IV.  Two  groups  were  assessed,  those  with  and  without  PIVH;  maternal  and  neonatal
control variables  were  used  for  comparison.  Univariate  and  multiple  regression  analyses  were
applied.
Results: A  total  of  125  newborns  were  assessed.  PIVH  incidence  rate  was  12.0%.  In  the  univariate
analysis, basal  ROI,  the  use  of  two  or  more  doses  of  corticosteroids,  birth  weight  <  1,000  g,
ventilatory  support  use,  and  SNAPPE  II  value  ≥  22  were  signiﬁcantly  associated  with  PIVH.
However, in  the  multivariate  analysis,  only  antenatal  steroid  use  was  independently  associated
with the  disease  (OR  0,194;  95%  CI:  0,048  to  0,773;  p=0,02).
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Conclusion:  ROI,  GSH,  and  IL-6  levels  were  not  associated  with  the  occurrence  of  PIVH  in  very-
low birth  weight  infants
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved.
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Recém-nascido
Hemorragia  peri-intraventricular  e  marcadores  de  estresse  oxidativo  e  inﬂamatório
em  RNs  de  muito  baixo  peso  ao  nascer
Resumo
Objetivos:  avaliar  a  associac¸ão  entre  marcadores  de  estresse  oxidativo  e  inﬂamatório  com  a
hemorragia  peri-  e  intraventricular  (HPIV)  em  recém-nascidos  (RN)  de  muito  baixo  peso  ao
nascer.
Métodos: estudo  prospectivo  em  unidade  neonatal  nível  III.  Foi  feita  dosagem  em  sangue  de
cordão umbilical  de  intermediários  reativos  de  oxigênio  (ROI)  basal  e  estimulado,  glutationa
reduzida (GR)  e  interleucina-6  (IL-6).  Recém-nascidos  foram  submetidos  à  ultrassonograﬁa  seri-
ada, à  beira  do  leito,  com  6,  12,  24  e  72  horas  de  vida  e  7  dias  para  o  diagnóstico  de  HPIV,
classiﬁcada  em  graus  de  I  a  IV.  Foram  avaliados  dois  grupos:  com  e  sem  HPIV  e  variáveis  de  con-
trole maternas  e  neonatais  foram  usadas  para  comparac¸ão.  Análise  univariada  e  de  regressão
múltipla foram  aplicados.
Resultados:  foram  avaliados  125  recém-nascidos.  A  taxa  de  incidência  de  HPIV  foi  de  12,0%.  Na
análise univariada  o  valor  basal  de  ROI,  o  uso  de  duas  ou  mais  doses  de  corticosteroide,  peso  ao
nascer menor  que  1.000  g,  o  uso  de  assistência  respiratória  e  valor  de  SNAPPE  II  maior  ou  igual
a 22  foram  signiﬁcativamente  associados  à  HPIV.  Porém,  na  análise  multivariada,  apenas  o  uso
antenatal  de  esteroides  se  mostrou  independentemente  associado  à  doenc¸a  (OR  0,194  IC95%
0,048-0,773  p=0,02).
Conclusão:  ROI,  GR  e  Il-6  não  foram  associados  à  ocorrência  de  HPIV  em  RN  de  muito  baixo
peso ao  nascer
© 2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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versity  neonatal  unit,  from  May  10,  2009  to  October  31,
2010.  Exclusion  criteria  were:  failure  to  collect  umbilicalntroduction
eri-intraventricular  hemorrhage  (PIVH)  remains  a  high-
revalence  disease  in  preterm  newborns,  especially  those
ith  birth  weight  <  1,500  g  and  gestational  age  <  34  weeks.
he  disease  is  associated  with  the  development  of  posthe-
orrhagic  hydrocephalus,  neurodevelopmental  disorders,
eed  for  specialized  rehabilitation  therapies,  and  high  social
osts.1,2
The  most  common  site  of  PIVH  is  the  germinal  matrix,
hich  is  located  in  the  periventricular  subependymal  region
nd  is  irrigated  by  fragile  and  immature  vasculature.  It  is  an
mportant  proliferation  site  of  neuronal  precursors  before
heir  migration  to  their  ﬁnal  location  in  the  cerebral  cortex.
everal  factors,  especially  those  related  to  cerebral  hypo-
erfusion  and  reperfusion  phenomena,  can  result  in  bleeding
t  this  site.2,3
In  addition  to  the  mechanism  of  vascular  rupture  associ-
ted  with  cerebral  blood  ﬂow  impairment,  PIVH  can  occur
ue  to  other  mechanisms,  which  may  be  of  vascular  origin
r  not.2
Experimental  studies  and  those  with  humans  have  showed
n  association  between  PIVH  and  oxidative  stress.  In  exper-
mental  studies  in  preterm  newborn  dogs,  Ment  et  al.
emonstrated  that  blocking  the  production  of  free  rad-
cals  with  etamsylate  and  indomethacin,  or  the  use  of
uperoxide-dismutase,  had  a  protective  effect  on  PIVH
c
bccurrence  after  reperfusion  injury  due  to  hypovolemic
ypotension.3--5
More  recently,  there  has  been  evidence  of  an  association
etween  PIVH  with  intrauterine  inﬂammatory-infectious
rocesses,6--8 as  well  as  an  association  between  serum
nterleukin-6  (IL-6)  levels  and  vascular  endothelium  matrix
esions  by  cytokines.9--11
However,  the  speciﬁc  evaluation  of  oxidative  stress
arkers  such  as  reactive  oxygen  species  and  glutathione
ntioxidant  enzyme  has  not  been  assessed  regarding  the
evelopment  of  PIVH.
This  study  aimed  to  evaluate  the  association  of  oxida-
ive  stress  markers,  speciﬁcally  the  production  of  reactive
xygen  intermediates  (ROIs)  and  reduced  glutathione  (GSH)
evels,  with  inﬂammation  markers,  namely  serum  IL-6  lev-
ls  measured  in  umbilical  cord  blood,  as  risk  factors  for  the
evelopment  of  PIVH.
ethods
his  was  a  prospective  cohort  study  that  included  all
reterm  newborns  (<  37  weeks  of  gestation)  with  a  birth
eight  <  1,500  g  who  were  hospitalized  at  a  level  3  uni-ord  blood;  maternal  or  guardian  refusal  to  allow  the  new-
orn  to  participate  in  the  study;  severe  malformation  of  the
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nOxidative  and  inﬂammatory  stress  and  PIVH  
central  nervous  system;  and  neonatal  death  within  six  hours
of  life,  preventing  the  performance  of  the  ﬁrst  cerebral
ultrasound.
Sample  size  was  calculated  according  to  the  umbili-
cal  cord  serum  levels  of  IL-6  as  a  marker  of  PIVH  onset
in  very-low  birth  weight  newborns,  based  on  the  study
by  Heep  et  al.,9 in  which  IL-6  was  categorized  into  val-
ues  >  100  pg/mL  or  ≤  100  pg/mL,  with  PIVH  rates  of  63%
and  38%  in  these  groups,  respectively.  Considering  a  5%
signiﬁcance  level,  a  test  power  of  80%,  and  a  local  PIVH
incidence  rate  of  20%,  the  calculated  minimum  sample  size
was  n  =  125.9
The  assessed  outcome  was  the  presence  of  peri-
intraventricular  hemorrhage  (PIVH),  dividing  patients  into
two  groups:  with  and  without  PIVH,  classiﬁed  according  to
Papile  et  al. 12
For  the  diagnosis  of  PIVH,  newborns  underwent  cerebral
ultrasound  at  the  bedside,  after  six,  12,  24,  and  72  hours  of
life  and  at  seven  days  of  age,  using  the  anterior  fontanel
as  acoustic  window  and  a  Xario®  (Toshiba®,  CA,  United
States)  echograph  with  a  5-mHz  transducer.  The  exams  were
recorded  and  stored  on  CD-ROMs  and  reviewed  by  two  expe-
rienced  evaluators.  In  case  of  doubt,  a  third  expert  was
called  to  give  his/her  opinion.
Umbilical  cord  blood  was  collected  at  birth  for  the  mea-
surement  of  biochemical  markers,  after  the  infant’s  birth
with  the  placenta  still  attached,  through  puncture  of  the
umbilical  vessels,  thus  yielding  a  mixed  sample,  both  arterial
and  venous.  Then,  the  material  was  distributed  into  three
vials,  two  with  an  anticoagulant  and  one  containing  silicon
oxalate  and  the  samples  were  processed  immediately.
The  measurement  of  ROI  production  from  polymorphonu-
clear  leukocytes  was  determined  using  ﬂow  cytometry  in
two  different  moments:  spontaneous  (or  basal)  production,
with  leukocytes  incubated  only  in  Hanks  solution;  and  the
stimulated  sample,  with  leukocytes  incubated  in  Phorbol-
myristate  acetate.13 Values  were  expressed  in  nMol  ×106
cells.
The  measurement  of  erythrocyte  GSH  levels  was  per-
formed  by  spectrophotometry:  the  assays  performed  in
duplicate  and  results  were  expressed  in  mg%  in  relation  to
hematocrit.14
IL-6  was  measured  in  samples  frozen  at  -80 ◦C  by  enzyme
linked  immunosorbent  assay  (ELISA),  according  to  the  manu-
facturer’s  instructions  (R&D  Systems®,  MN,  United  States).15
For  comparison  between  groups,  the  following  maternal
and  neonatal  control  variables  that  could  interfere  with  the
PIVH  outcome  were  further  analyzed:  primiparity,  hyperten-
sive  disease,  use  of  antenatal  corticosteroids  and  number
of  doses  ≥  2,  vaginal  delivery,  cephalic  presentation,
chorioamnionitis,  twin  pregnancy,  birth  weight  <  1,000  g,
gestational  age  <  30  weeks,  male  gender,  Apgar  score  <  7  at
the  ﬁrst  and  ﬁfth  minutes,  need  for  resuscitation,  small  for
gestational  age,  ventilatory  support,  use  of  surfactant,  and
Score  for  Neonatal  Acute  Physiology  and  Perinatal  Extension
(SNAPPE)  II  value.
Maternal  hypertensive  disease  was  deﬁned  as  the  pres-
ence  of  systolic  blood  pressure  (SBP)  ≥  140  mmHg  or  higher
and  diastolic  blood  pressure  (DBP)  ≥  90  mmHg,  in  two  mea-
surements,  with  an  interval  of  at  least  four  hours  between
them,  or  the  presence  of  SBP  ≥  160  mmHg  and  DBP  ≥
110  mmHg  in  a  single  measurement.16 Chorioamnionitis  was
f
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eﬁned  as  the  presence  of  maternal  fever  (maternal  tem-
erature  ≥  37.8◦ C)  combined  with  two  or  more  of  the
ollowing  signs:  pain  on  uterine  palpation,  fetid/purulent
mniotic  ﬂuid,  fetal  tachycardia  (>  160  bpm),  maternal
achycardia  (>  100  bpm)  and  leukocytosis  (total  leukocyte
ount  >  15,000/mL).17 Small  for  gestational  age  was  deﬁned
s  the  newborn  with  birth  weight  <  10th percentile,  according
o  the  fetal  growth  curve  of  Alexander  et  al.18
For  SNAPPE  II,  ROI,  GSH,  and  IL-6  values,  the  cutoff  for
ategorization  was  obtained  through  the  maximization  of
he  area  under  the  curve  (AUC).
Clinical  variables  were  only  considered  present  or  absent
t  the  time  of  detection  of  PIVH  by  serial  ultrasound.  In  case
f  absence  of  PIVH  development,  variables  were  assessed
ntil  the  seventh  day  of  life.
For  statistical  analysis,  birth  weight,  gestational  age,
aternal  age,  and  ROI  production  values,  as  well  as  blood
evels  of  GHS  and  IL-6,  were  expressed  as  medians  and  25th
nd  75th percentiles,  and  were  assessed  by  Mann-Whitney
est.  The  chi-squared  test  or  Fisher’s  test  were  used  to
ompare  categorical  variables.  Step-by-step  multiple  logis-
ic  regression  analysis  was  applied  to  verify  the  independent
ariables  with  the  occurrence  of  PIVH  outcome,  adapted  for
he  calculation  of  incidence  ratio  using  the  variables  that
howed  signiﬁcance  level  ≥  0.2  in  the  univariate  analysis.
he  signiﬁcance  level  was  set  at  p  <  0.05.
The  SPSS,  release  15.0  for  Windows  (SPSS  Inc.  Statistics
or  Windows,  Chicago,  United  States)  was  used  in  all  statisti-
al  analyses.  Parents  signed  an  informed  consent.  The  study
as  approved  by  the  local  Research  Ethics  Committee  under
o.  971/2008.
esults
uring  the  study  period,  138  children  with  birth
eight  <  1,500  g  were  eligible  for  inclusion.  Of  these,
3  were  not  included  in  the  present  study,  as  umbilical
ord  blood  collection  was  not  possible  in  12  children;  two
f  these  had  PIVH  (16.66%),  one  with  grade  I and  another,
rade  III.  One  newborn  was  excluded  because,  although
ord  blood  had  been  collected,  he  died  within  less  than  six
ours  of  life,  which  prevented  the  ultrasound  assessment.
A  total  of  125  children  were  included  in  the  study.  The
umber  of  mothers  was  111,  as  there  were  14  multiple  preg-
ancies,  11  twin  and  three  triplet  pregnancies.  There  was
o  maternal  refusal  to  participate.
Of  the  125  children  studied,  15  had  PIVH  (12.0%),  six  of
hem  with  grade  I,  two  with  grade  II,  four  with  grade  III,  and
hree  with  grade  IV.  The  mild  form  of  the  disease  (grades  I
nd  II)  occurred  on  eight  cases  (53.33%),  and  the  severe  form
grades  III  and  IV)  in  seven  newborns  (46.66%).  The  PIVH  rate
n  the  group  that  was  not  included  was  similar  to  that  of  the
tudy  group  (16.6%  vs.  12.0%;  p  =  0.342).
In  four  cases  (26.67%),  PIVH  was  diagnosed  within  six
ours  of  life,  including  the  severe  form  of  the  disease,  and
early  half  (46.6%)  was  observed  at  up  to  24  hours  of  life.
There  were  14  deaths  among  the  study  population  and
our  of  these  newborns  (28.57%)  had  the  severe  forms  of  the
isease  (three  newborns  were  grade  III  and  one  was  grade
V).  All  but  three  deaths  occurred  after  72  hours  of  life.  Of
he  three  patients  who  died  between  six  and  72  hours  of
376  Caldas  JP  et  al.
Table  1  Basal  and  stimulated  ROI  values,  glutathione,  and  IL-6  levels  in  umbilical  cord  blood  of  very  low  birth  weight  preterm
newborn, according  to  the  occurrence  of  PIVH.
PIVH  pa
Markers  N  Present  n  Absent
bROI  14  0.50  (0.4-0.6)  103  0.40  (0.4-0.5)  0.045
sROI 14  38.65  (17.15--66.70)  103  39.60  (18.60-138.25)  0.355
GSH 13  67.25  (56.71-78.31)  103  71.03  (63.37-80.83)  0.337
IL-6 14  24.34  (14.42-72.15)  107  34.20  (13.98-62.58)  0.903
a Mann-Whitney test.
Values in median (p25-p75).
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although  prematurity  itself  is  the  main  risk  factor  for  the
disease,  the  deﬁnition  of  gestational  age  may  not  be  exact
due  to  the  inaccuracy  of  measurement  methods.  National
and  international  research  networks  have  also  used  birth
Table  2  Distribution  of  PIVH  occurrence  according  to  the
categorical  control  variables.
PIVH
Present  (15) Absent  (110) p
Primiparity  7  (46.66)  56  (50.90)  0.757
Hypertensive
disease
5 (33.33)  53  (48.18)  0.279
ANC 10  (66.66)  93  (84.54)  0.139
No. doses  of
ANC  ≥  2
5  (33.33)  82  (74.54)  0.003
Vaginal  delivery  6  (40.0)  20  (18.19)  0.083
Cephalic  pres.  11(73.33)  82  (74.55)  1.000
Chorioamnionitis  3  (20.0)  7  (6.36)  0.100
Twin pregnancy  2  (13.33)  33  (30.0)  0.230
Birth
weight  <  1,000  g
12  (80.0)  48  (43.64)  0.008
Gestational
age <  30
weeks
11 (73.33)  69  (62.72)  0.166
Male gender  9  (60.0)  58  (52.73)  0.783
Apgar 1st
minute  <  7
6  (40.0)  39  (35.46)  0.730
Apgar 5th
minute  <  7
2  (13.33)  7  (6.37)  0.294
Resuscitation  7  (46.67)  42  (38.19)  0.527
SGA 11  (73.33)  61  (55.46)  0.188
Ventilatory
Support
15(100) 84  (76.37)  0.039
Surfactant  13  (86.67)  58  (52.72)  0.341
SNAPPE  II  ≥  22  11  (73.33)  41  (37.28)  0.007N, number of cases; bROI, basal ROI; sROI, stimulated ROI (value
interleukin-6 (values in pg/mL)
ife,  one  of  them  already  had  a  diagnosis  of  parenchymal
emorrhage  at  the  cerebral  ultrasound  (grade  IV  of  Papille
t  al.)12 and  was  classiﬁed  as  ‘‘presence  of  PIVH’’.  The  other
wo  cases  died  after  31  and  43  hours  of  life,  without  hem-
rrhagic  lesion  at  the  ultrasound  at  6/12/24  hours  of  life,
ith  no  PIVH  at  necropsy,  and  were  therefore  classiﬁed  as
‘absence  of  PIVH’’.
When  assessing  the  markers,  it  was  observed  that  the
asal  ROI  production  showed  a  statistically  higher  median
n  the  group  with  PIVH  (p  =  0.045).  However,  the  stimulated
roduction  showed  no  statistical  difference.  The  median
lutathione  and  IL-6  values  also  showed  no  statistically  sig-
iﬁcant  difference  between  the  groups  (Table  1).
Regarding  control  clinical  variables,  the  group  with  signif-
cantly  PIVH  had  the  lowest  median  birth  weight  (870  versus
,042  g;  p  =  0.017),  gestational  age  (27  versus  29  weeks;
 =  0.014)  and  higher  values  of  SNAPPE  II  (26  versus  17;
 =  0.016).
Regarding  the  use  of  antenatal  betamethasone,  it  was
bserved  that  82.4%  (103/125)  of  the  newborns  received  the
edication,  and  87  of  them  received  the  complete  cycle,
ut  no  signiﬁcant  difference  was  observed  in  the  incidence
f  PIVH  (10/15  versus  93/110;  p  =  0.1395).  However,  when
he  use  of  corticosteroids  was  assessed  according  to  the
umber  of  doses  used,  it  was  observed  that  the  use  of  two
r  more  doses  of  betamethasone  was  more  statistically  fre-
uent  (p  =  0.003)  in  the  group  without  PIVH  (Table  2).
Regarding  the  other  control  variables,  in  the  univari-
te  analysis,  PIVH  was  signiﬁcantly  associated  with  birth
eight  <  1,000  g,  use  of  two  or  more  doses  of  antenatal  cor-
icosteroids,  respiratory  assistance,  and  SNAPPE-II  values
 22.  The  other  variables  were  not  signiﬁcantly  different
etween  the  two  groups  (Table  2).
The  following  variables  remained  in  the  multivari-
te  analysis:  basal  ROI  (>  0.5  nMol  ×  106 cells),  two
r  more  doses  of  corticosteroids,  vaginal  delivery,  birth
eight  <  1,000  g,  gestational  age  ≤  30  weeks,  nutritional  sta-
us,  and  SNAPPE  ≥  22.  At  the  ﬁnal  result  of  the  multiple
nalysis,  ROI  production  was  not  independently  associated
ith  the  occurrence  of  the  disease.  It  was  observed  that  only
he  antenatal  use  of  two  or  more  doses  of  corticosteroids
as  independently  associated  with  PIVH,  as  a  protective
actor  (OR  0.194;  95%CI:  0.048  to  0.773;  p  =  0.02;  Table  3).
lutathione  and  IL-6  levels  were  not  included  in  the  ﬁnal
ultivariate  regression  model,  as  they  did  not  show  statis-
ical  difference  in  the  univariate  model.Mol × 106 cells); GSH, reduced glutathione (values in mg%); Il-6,
iscussion
he  study  comprised  a  population  of  newborns  at  risk  for
IVH.  Birth  weight  was  used  as  the  inclusion  criterion,  sinceCategorical variables expressed as a percentage.
ANC, antenatal corticosteroid; SGA, small for gestational age;
SNAPPE II, Score for Neonatal Acute Physiology and Perinatal
Extension
Oxidative  and  inﬂammatory  stress  and  PIVH  
Table  3  Multiple  regression  analysis  to  assess  variables
associated  with  PIVH  in  very-low  birth  weight  newborns.
Variable  OR  95%  CI  p
Basal  ROI  ≥  0.5 3.16 0.62 16.13  0.165
Dose ANC  ≥  2
versus  0
0.19  0.04  0.77  0.02
Vaginal  delivery  1.20  0.15  9.52  0.857
Chorioamnionitis  2.53  0.26  24.04  0.418
Birth
weight  <  1,000  g
3.90  0.40  37.44  0.237
Gestational  age
≤ 30  weeks
2.46  0.15  40.60  0.524
SGA 0.46 0.03 6.84 0.557
SNAPPE  II  ≥22  1.00  0.26  7.46  0.998
OR, odds ratio; 95% CI, 95% conﬁdence interval, ROI, reactive
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toxygen intermediates; ANC, antenatal corticosteroid; SGA, small
for gestational age; SNAPPE II, Score for Neonatal Acute Physi-
ology and Perinatal Extension.
weight  as  an  inclusion  criterion,  facilitating  data  comparison
between  the  units.19--21
Cerebral  ultrasound  was  performed  within  the  ﬁrst  hours
of  life,  as  the  early  perinatal  and  neonatal  risk  factors  are
very  important  for  the  onset  of  PIVH;  therefore,  the  analy-
sis  of  blood  markers  for  PIVH  could  be  timely  conducted.  In
the  present  study,  the  disease  was  detected  within  the  ﬁrst
hours  of  life,  as  almost  50%  of  hemorrhage  cases  occurred
up  to  24  hours  of  life,  which  is  in  agreement  with  other
studies.22 In  addition  to  the  diagnostic  aspect,  performing
an  early  serial  ultrasound  assessment  allowed  for  a  more
appropriate  selection  of  neonatal  risk  factors  present  at  a
certain  moment,  as  well  as  for  establishing  their  associa-
tion  with  the  disease  diagnosis.  Many  of  the  studies  that
assessed  the  risk  factors  for  PIVH  considered  the  occurrence
of  the  disease  within  seven  days  of  life  and,  therefore,  it
was  not  possible  to  accurately  identify  the  decisive  factor
in  the  disease  genesis.23
Basal  ROI  production  was  signiﬁcantly  higher  in  newborns
who  later  developed  PIVH.  This  fact  implies  that  leukocytes
had  a  signiﬁcant  activation  potential  at  birth  and  could  par-
ticipate  in  events  related  to  oxidative  damage.
Studies  have  shown  that  in  normal  full-term  newborns,
the  production  of  superoxide  anions  by  polymorphonuclear
leukocytes  from  blood  of  the  umbilical  cord  was  signiﬁcantly
higher  when  the  delivery  was  vaginal,  when  compared  with
blood  samples  from  newborns  whose  mothers  had  under-
gone  cesarean  delivery,  without  labor.  This  suggests  that
leukocyte  activation  is  part  of  the  mechanisms  of  parturition
and  normal  birth  processes.  However,  in  preterm  labor,  that
leukocyte  activation  in  the  fetus  could  cause  tissue  cell  dam-
age,  either  due  to  intensity  of  the  reaction  or  the  functional
immaturity.24,25
Perrone  et  al.  evaluated  the  basal  and  stimulated  pro-
duction  of  superoxide  anions  in  168  preterm  newborns  with
24-32  weeks  gestation.  When  assessing  several  neonatal
oxidative  diseases  related  to  oxidative  stress,  the  authors
found  no  difference  in  superoxide  anion  production  by  cord
blood  leukocytes.  However,  the  authors  did  not  comment  on
the  data  regarding  PIVH  alone,  due  to  the  small  number  of
cases.26
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Stimulated  ROI  production  was  not  different  in  both
roups.  This  fact  could  be  explained  either  because  the  pro-
uction  in  the  group  with  PIVH  was  already  at  its  maximum,
r,  as  this  is  an  artiﬁcial  in  vitro  stimulation,  it  may  not
eﬂect  the  complex  conditions  in  vivo  biological  stimuli.
n  a study  of  polymorphonuclear  leukocytes  in  full-term
ewborns,  it  was  demonstrated  that  the  generation  of  super-
xide  radicals  increased  signiﬁcantly  after  stimulation  with
ts  N-formyl-methionyl-leucyl-phenylalanine,  but  there  was
o  additional  increase  when  IL-10  or  dexamethasone  was
dded  to  the  culture  medium.27
As  for  glutathione,  there  was  no  difference  in  the  val-
es  observed  in  both  groups.  Studies  have  shown  that,  as
he  pregnancy  reaches  term,  the  antioxidant  system  blood
evels,  both  enzymatic  or  not,  increase  gradually  and  act  as
 protective  factor  for  the  relative  hyperoxia  that  follows
irth.  Therefore,  the  low  reserve  of  a  non-enzymatic  antiox-
dant  system  at  a  preterm  birth  exposes  the  newborn  to  a
reater  risk  of  oxidative  damage.28,29 However,  the  low  sam-
le  power  of  the  test  for  glutathione  found  in  the  present
tudy  (11.5%),  prevents  generalizations  regarding  the  exist-
nce  of  a protective  effect  or  not.
The  IL-6  serum  levels  were  not  different  in  patients  with
nd  without  PIVH.  This  result  could  be  justiﬁed  by  the  low
ncidence  of  clinical  chorioamnionitis  in  the  population  (8%).
urthermore,  the  prior  effective  antimicrobial  treatment  of
he  mothers,  which  is  routine  practice  in  our  service,  could
ave  reduced  fetal  levels  of  cytokines,  as  they  have  short
alf-lives.30--32
The  high  incidence  of  hypertension  in  the  sample
46.4%),  may  also  explain  the  lack  of  association  between
nﬂammation  markers  and  PIVH.  Experimentally,  Kauma
t  al.  demonstrated  that  hypertensive  women’s  placentas
roduced  lower  amounts  of  IL-6  when  compared  with  nor-
otensive  pregnant  women.33 Antenatal  corticosteroid  use
ould  also  alter  placental  IL-6  production,  as  shown  in  pla-
ental  cell  cultures34 and  in  a  study  with  humans.32
Studies  that  have  shown  an  association  of  PIVH  with
ncreased  levels  of  IL-6  have  some  aspects  that  justify
uch  difference,  such  as  more  premature  newborns  and,
herefore,  more  susceptible  to  PIVH,  selected  population
pregnant  women  with  clinical  suspicion  of  chorioamnioni-
is),  higher  incidence  of  histological  chorioamnionitis  in  the
ample  and  IL-6  measurement  in  the  newborn’s  blood  and
ot  umbilical  cord  blood.9--11 In  the  study  by  Bhandari  et  al.,
L-6  levels  in  cord  blood  were  signiﬁcantly  higher  in  the
roup  that  developed  PIVH,  but  in  the  regression  analysis
sing  clinical  variables  with  correction  for  gestational  age,
L-6  levels  were  not  independently  associated  with  PIVH.35
The  clinical  variables  may  have  interfered  with  the  bio-
hemical  results  as  previously  mentioned.  Of  the  variables
tudied,  only  the  antenatal  use  of  two  or  more  doses  of  corti-
osteroids  was  associated  (as  a  protective  factor),  with  the
evelopment  of  PIVH,  which  is  consistent  with  the  litera-
ure.  A  systematic  review  showed  that  antenatal  steroid  use
romoted  a  signiﬁcant  reduction  in  the  incidence  of  PIVH,
onsidering  all  forms  of  the  disease  (RR  0.54;  95%  CI:  0.43
o  0.69)  and  in  the  prevention  of  severe  forms  (RR  0.28;
5%  CI:  0.16  to  0.50).  However,  protection  was  not  observed
hen  the  birth  occurred  before  24  hours  of  the  administra-
ion  of  the  ﬁrst  dose  (RR  0.54;  95%CI:  0.21  to  1.36),  but
as  observed  when  birth  occurred  before  48  hours  after  the
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278  
dministration  of  the  ﬁrst  dose  (RR  0.26;  95%CI:  0.09  to
.75).36
Steroid  use  alone  is  capable  of  altering  the  response  of
he  assessed  biomarkers,  with  decreased  production  of  ROI
nd  IL-6,27,32,34,37 and  may  therefore  prevent  such  markers
rom  expressing  themselves  and  being  factors  independently
ssociated  with  PIVH.  However,  studies  with  controlled
xposure  to  antenatal  steroid  use,  in  case  of  premature  birth
anger,  would  not  be  ethical.
onclusion
n  conclusion,  the  basal  production  of  ROI  from  umbili-
al  cord  blood  was  statistically  higher  in  newborns  that
eveloped  PIVH;  however,  in  the  multivariate  analysis,  the
aseline  ROI  levels  were  not  statistically  an  independent
isk  factor  for  HPIV.  IL-6  or  glutathione  levels  were  also  not
ssociated  with  the  PIVH.
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